News - Stallergenes, CNS Diseases

Filter

Current filters:

StallergenesCNS Diseases

Popular Filters

US FDA approves Stallergenes’ allergy tablet Oralair

US FDA approves Stallergenes’ allergy tablet Oralair

02-04-2014

The US Food and Drug Administration has approved Oralair immunotherapy tablet from French allergen specialist…

ImmunologicalsOralairPharmaceuticalRegulationStallergenesUSA

NICE asks Biogen Idec for more information on Tecfidera

NICE asks Biogen Idec for more information on Tecfidera

21-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) is calling on US biotech firm Biogen…

Biogen IdecBiotechnologyCNS DiseasesRegulationTecfideraUK

Prana reports successful Phase II results in Huntington disease trial

18-02-2014

Australia-based Prana Biotechnology has announced positive results of its Reach2HD Phase II clinical…

AustraliaBiotechnologyCNS DiseasesNeurologicalPrana BiotechnologyResearch

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Stallergenes' Oralair gains US FDA panel backing

Stallergenes' Oralair gains US FDA panel backing

12-12-2013

France’s Stallergenes said late yesterday that the Allergenic Products Advisory Committee (APAC) of…

GREER LaboratoriesImmunologicalsNorth AmericaOralairPharmaceuticalRegulationStallergenes

Stallergenes links with ActoGeniX on new class of oral allergy treatments

03-12-2013

French allergen specialist Stallergenes and ActoGeniX NV, creator of ActoBiotics, have entered into an…

ActoBioticsActoGeniXImmunologicalsLicensingPharmaceuticalResearchStallergenes

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland

27-11-2013

UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

Collaboration agreement between French firms Vect-Horus and AAA

20-11-2013

French biotech company Vect-Horus has signed a scientific collaboration agreement with Advanced Accelerator…

Advanced Accelerator ApplicationsBiotechnologyCNS DiseasesEuropeLicensingMergers & AcquisitionsVect-Horus

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

Sanofi’s Lemtrada gets support from FDA advisory panel

Sanofi’s Lemtrada gets support from FDA advisory panel

14-11-2013

French drug major Sanofi (Euronext: SAN) has received support from a US Food and Drug Administration…

CNS DiseasesEuropeGenzymeLemtradaPharmaceuticalRegulationSanofi

Greer Labs and Stallergenes in deal for Oralair in USA

31-10-2013

French allergy specialists Stallergenes and USA-based Greer Laboratories have signed an exclusive agreement…

GREER LaboratoriesImmunologicalsLicensingNorth AmericaOralairPharmaceuticalStallergenes

Stallergenes report growth in third quarter results

22-10-2013

French allergy specialists Stallergenes has released its third quarter results showing revenue growth…

EuropeFinancialImmunologicalsOralairPharmaceuticalStallergenes

Stallergenes and DBV Technologies collaborate in birch pollen allergy research

18-10-2013

French allergy specialists Stallergenes and DBV Technologies, creator of Viaskin for the treatment of…

DBV TechnologiesImmunologicalsPharmaceuticalResearchRespiratory and PulmonaryStallergenes

Novartis MS drug Gilenya leads to reduction in brain volume drug

Novartis MS drug Gilenya leads to reduction in brain volume drug

04-10-2013

Novartis has revealed new data indicating that continued treatment with Gilenya led to a reduction in…

CNS DiseasesEuropeGilenyaNovartisPharmaceuticalResearch

Inovio reveals success in DNA plasmid technology

Inovio reveals success in DNA plasmid technology

25-09-2013

US drug developer Inovio Pharmaceuticals has demonstrated the success of its new DNA plasmid technology…

Anti-Arthritics/RheumaticsBiotechnologyCNS DiseasesInovio PharmaceuticalsNorth AmericaOncologyResearch

Stallergenes and DBV Technologies partner on developing novel respiratory allergies treatments

20-05-2013

French biotech firms DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the treatment…

BiotechnologyDBV TechnologiesLicensingResearchRespiratory and PulmonaryStallergenes

Stallergenes adds France to roll-out of grass pollen therapy Oralair

22-11-2012

France-based Stallergenes (GENP: FP) has announced the launch in France of Oralair, its grass pollen…

EuropeMarkets & MarketingOralairPharmaceuticalRespiratory and PulmonaryStallergenes

Back to top